STAT's latest Readout newsletter leads with news that RevMed's pancreatic cancer drug is nearing European approval. The update was reported by Meghana Keshavan and Andrew Joseph, though the full details are behind STAT's subscriber paywall.
The newsletter also flags Merck and Moderna's plans to expand their cancer vaccine efforts, following earlier signs of success, as well as China's growing influence on global venture investing in biotech. These are separate items within the same briefing, not connected developments.
No additional clinical or regulatory specifics about RevMed's drug were included in the available excerpt, so the significance rests on the proximity of a potential approval in Europe for a cancer type with few effective treatment options.